Moshe Arkin 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-02 2:23 pm Sale | 2023-01-26 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,371,074 4.980% | -441,241 (-24.35%) | Filing |
| 2022-04-12 06:18 am Unchanged | 2022-04-11 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,812,315 7.550% | 0 (Unchanged) | Filing |
| 2022-04-11 4:57 pm Sale | 2022-04-11 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,812,315 7.550% | -223,825 (-10.99%) | Filing |
| 2020-12-17 06:48 am Unchanged | 2020-12-17 | 13D | Keros Therapeutics, Inc. KROS | Moshe Arkin | 2,036,140 8.790% | 0 (Unchanged) | Filing |
| 2020-11-25 06:31 am Unchanged | 2020-11-17 | 13D | Keros Therapeutics, Inc. KROS | Moshe Arkin | 2,036,140 8.790% | 0 (Unchanged) | Filing |
| 2020-04-20 1:14 pm Purchase | 2020-04-08 | 13D | Keros Therapeutics, Inc. KROS | Moshe Arkin | 2,036,140 10.600% | 2,036,140 (New Position) | Filing |